Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass

NCT ID: NCT06013189

Last Updated: 2023-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-07

Study Completion Date

2034-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators designed this prospective observational study with the theory that alkalosis caused by decreased CO2 solubility due to temperature increase during the rewarming period of the Cardiopulmonary Bypass could be prevented by reducing the sweep gas flow during the rewarming period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Optimal Sweep Gas Flow Determination of Optimal Sweep Gas Flow for Different Phases of Cardiopulmonary Bypass

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Sweep Gas Flow did not changed (1.35 L/m2/min)

No interventions assigned to this group

Group 2

Sweep Gas Flow decreased during rewarming (1.2 L/m2/min)

Gas Flow Adjustment

Intervention Type OTHER

Decreased gas flow causes PaCO2 to elevate and prevents alkalosis

Group 3

Sweep Gas Flow decreased during rewarming (1 L/m2/min)

Gas Flow Adjustment

Intervention Type OTHER

Decreased gas flow causes PaCO2 to elevate and prevents alkalosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gas Flow Adjustment

Decreased gas flow causes PaCO2 to elevate and prevents alkalosis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years of age
* Elective CPB surgery

Exclusion Criteria

* Patients undergoing minimally invasive surgery
* Patients undergoing robotic cardiac surgery,
* Patients undergoing deep hypothermia,
* Patients undergoing total circulatory arrest,
* Patients whose FiO2 requirement is high that cannot be applied to target gas flow
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acıbadem Atunizade Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Melis Tosun

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Acıbadem Altunizade Hastanesi İstanbul

Istanbul, Altunizade, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Melis Tosun, MD

Role: CONTACT

00905356694002

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Melis Tosun, MD

Role: primary

00905356694002

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ATADEK 2019-19/21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.